Literature DB >> 16078848

Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.

Ana Belén Bueno1, Iván Collado, Alfonso de Dios, Carmen Domínguez, José Alfredo Martín, Luisa M Martín, María Angeles Martínez-Grau, Carlos Montero, Concepción Pedregal, John Catlow, D Scott Coffey, Michael P Clay, Anne H Dantzig, Terry Lindstrom, James A Monn, Haiyan Jiang, Darryle D Schoepp, Robert E Stratford, Linda B Tabas, Joseph P Tizzano, Rebecca A Wright, Marc F Herin.   

Abstract

(+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (1), also known as LY354740, is a highly potent and selective agonist for group II metabotropic glutamate receptors (mGlu receptors 2 and 3) tested in clinical trials. It has been shown to block anxiety in the fear-potentiated startle model. Its relatively low bioavailability in different animal species drove the need for an effective prodrug form that would produce a therapeutic response at lower doses for the treatment of anxiety disorders. We have investigated the increase of intestinal absorption of this compound by targeting the human peptide transporter hPepT1 for active transport of di- and tripeptides derived from 1. We have found that oral administration of an N dipeptide derivative of 1 (12a) in rats shows up to an 8-fold increase in drug absorption and a 300-fold increase in potency in the fear-potentiated startle model in rats when compared with the parent drug 1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078848     DOI: 10.1021/jm050235r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

Review 2.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

Review 3.  Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.

Authors:  John H Krystal; Sanjay J Mathew; D Cyril D'Souza; Amir Garakani; Handan Gunduz-Bruce; Dennis S Charney
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

4.  Recent Progress on the Stereoselective Synthesis of Cyclic Quaternary alpha-Amino Acids.

Authors:  Carlos Cativiela; Mario Ordóñez
Journal:  Tetrahedron Asymmetry       Date:  2009-01-30

5.  Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models.

Authors:  Michael P Johnson; Mark A Muhlhauser; Eric S Nisenbaum; Rosa M A Simmons; Beth M Forster; Kelly L Knopp; Lijuan Yang; Denise Morrow; Dominic L Li; Jeffrey D Kennedy; Steven Swanson; James A Monn
Journal:  Br J Pharmacol       Date:  2017-03-13       Impact factor: 8.739

Review 6.  Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.

Authors:  R E Nordquist; T Steckler; J G Wettstein; C Mackie; W Spooren
Journal:  Psychopharmacology (Berl)       Date:  2008-03-06       Impact factor: 4.530

7.  In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Authors:  Linda M Rorick-Kehn; Bryan G Johnson; Karen M Knitowski; Craig R Salhoff; Jeffrey M Witkin; Kenneth W Perry; Kelly I Griffey; Joseph P Tizzano; James A Monn; David L McKinzie; Darryle D Schoepp
Journal:  Psychopharmacology (Berl)       Date:  2007-03-24       Impact factor: 4.415

8.  PEPT1-mediated prodrug strategy for oral delivery of peramivir.

Authors:  Yongbing Sun; Wei Gan; Mingdao Lei; Wei Jiang; Meng Cheng; Junwei He; Qi Sun; Wan Liu; Lvjiang Hu; Yi Jin
Journal:  Asian J Pharm Sci       Date:  2018-10-03       Impact factor: 6.598

Review 9.  Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery.

Authors:  Paulina Cieślik; Joanna M Wierońska
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

10.  Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia.

Authors:  Kohnosuke Kinoshita; Motoki Ochi; Katsuya Iwata; Misako Fukasawa; Jun-Ichi Yamaguchi
Journal:  Pharmacol Res Perspect       Date:  2019-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.